8.91
Electrocore Inc stock is traded at $8.91, with a volume of 617.53K.
It is up +33.58% in the last 24 hours and up +44.29% over the past month.
electroCore Inc is a bioelectronic technology company whose mission is to improve health and quality of life through non-invasive bioelectronic technologies. Its two commercial products are gammaCore non-invasive vagus nerve stimulation, or nVNS, and Quell Fibromyalgia, or Quell. It also sells Truvaga and TAC-STIM products, which are handheld, personal-use consumer products developed to promote general wellness and human performance. It operates in one segment: Bioelectronic Innovations. Geographically, it operates in the United States, the United Kingdom, Japan, and Other.
See More
Previous Close:
$6.67
Open:
$6.79
24h Volume:
617.53K
Relative Volume:
8.44
Market Cap:
$73.91M
Revenue:
$32.03M
Net Income/Loss:
$-13.97M
P/E Ratio:
-5.2756
EPS:
-1.6889
Net Cash Flow:
$-8.25M
1W Performance:
+50.89%
1M Performance:
+44.29%
6M Performance:
+81.84%
1Y Performance:
+79.28%
Electrocore Inc Stock (ECOR) Company Profile
Name
Electrocore Inc
Sector
Industry
Phone
973-290-0097
Address
200 FORGE WAY, ROCKAWAY
Compare ECOR vs ABT, SYK, MDT, BSX, EW
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
|
ECOR
Electrocore Inc
|
8.91 | 55.33M | 32.03M | -13.97M | -8.25M | -1.6889 |
|
ABT
Abbott Laboratories
|
86.67 | 152.25B | 45.13B | 6.28B | 7.38B | 3.5895 |
|
SYK
Stryker Corp
|
313.00 | 121.33B | 25.27B | 3.34B | 4.57B | 8.6334 |
|
MDT
Medtronic Plc
|
77.60 | 100.91B | 35.48B | 4.64B | 5.41B | 3.582 |
|
BSX
Boston Scientific Corp
|
57.64 | 85.88B | 20.62B | 3.56B | 3.48B | 2.3847 |
|
EW
Edwards Lifesciences Corp
|
87.54 | 49.39B | 6.30B | 1.07B | 1.09B | 1.8406 |
Electrocore Inc Stock (ECOR) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-14-20 | Upgrade | BTIG Research | Neutral → Buy |
| Nov-14-19 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
| Sep-26-19 | Resumed | Cantor Fitzgerald | Neutral |
| May-30-19 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| May-15-19 | Downgrade | BTIG Research | Buy → Neutral |
| May-09-19 | Initiated | Noble Capital Markets | Outperform |
| Sep-21-18 | Initiated | Cantor Fitzgerald | Overweight |
View All
Electrocore Inc Stock (ECOR) Latest News
Electrocore director Thomas J. Errico buys $59,852 in stock By Investing.com - Investing.com Nigeria
electroCore Stock (ECOR) Opinions on Recent Surge and Clinical Validation - Quiver Quantitative
Electrocore director Thomas J. Errico buys $59,852 in stock - Investing.com
electroCore (ECOR) director boosts stake with 9,992-share open-market buy - Stock Titan
ElectroCore touts 30% growth outlook, VA opportunity at LD Micro Conference - MSN
ElectroCore CFO sells $19,500 in shares - Investing.com India
ElectroCore CFO sells $19,500 in shares By Investing.com - Investing.com Nigeria
electroCore (ECOR) CFO sells 3,000 shares to cover RSU taxes - Stock Titan
Electrocore Stock Price Forecast. Should You Buy ECOR? - StockInvest.us
electroCore Touts 30% Growth Outlook, VA Opportunity at LD Micro Conference - Yahoo Finance
Relay Therapeutics (RLAY) surges 16.4%: Is this an indication of further gains? - MSN
ECOR: Rapid growth, unique vagus nerve tech, and new partnerships drive future expansion - TradingView
electroCore (ECOR) Stock: Down -2.49%, Support Test at $5.96 2026-05-17Dealer Delta - Newser
ElectroCore to Present at the LD Micro Invitational XVI Conference on May 18, 2026 - marketscreener.com
electroCore (ECOR) Drops -5.29% — Key Support at $5.79 2026-05-15Imbalance Zone - Newser
electroCore (ECOR) Q1 2026 Earnings Transcript - AOL.com
Vagus Nerve Stimulators Market to Reach USD 1.86 Billion by 2033 - openPR.com
ECOR (NASDAQ) brokered sale notice: 45,000 shares valued $291,600 - Stock Titan
Quell device shows pain reduction in fibromyalgia study By Investing.com - Investing.com India
electroCore (ECOR) Reports Positive Fibromyalgia Trial Results - GuruFocus
Quell device shows pain reduction in fibromyalgia study - Investing.com
electroCore Announces Publication in JAMA Highlighting the Benefits of Adding Quell Electrical Nerve Stimulation to Outpatient Physical Therapy in Fibromyalgia - The Manila Times
electroCore Announces Publication in JAMA Highlighting the - GlobeNewswire
Wearable nerve stimulator eases fibromyalgia pain in JAMA trial - Stock Titan
Q2 Earnings Forecast for electroCore Issued By HC Wainwright - MarketBeat
Brokers Set Expectations for electroCore Q2 Earnings - MarketBeat
Number of shareholders of electroCore, Inc. – NASDAQ:ECOR - TradingView
Q1 Earnings Forecast for electroCore Issued By HC Wainwright - MarketBeat
ElectroCore reaffirms 2026 revenue guidance of ~30% growth while targeting deeper VA utilization - MSN
electroCore to Present at the LD Micro Invitational XVI Conference on May 18, 2026 - Sahm
electroCore to present at LD Micro Invitational XVI on May 18, 2026, highlighting bioelectronic medicine advances - Pluang
electroCore to Present at LD Micro Invitational XVI Conference on May 18, 2026 - geneonline.com
Analysts Are Bullish on These Healthcare Stocks: Electrocore (ECOR), Warby Parker (WRBY) - The Globe and Mail
Maxim Group Maintains ElectroCore(ECOR.US) With Buy Rating, Maintains Target Price $12 - Moomoo
electroCore (ECOR) Reports Strong Q1 Revenue Growth - GuruFocus
ECOR Forecasts 30% Revenue Growth for 2026 - GuruFocus
ElectroCore Q1 earnings preview - MSN
electroCore, Inc. (NASDAQ:ECOR) Q1 2026 Earnings Call Transcript - Insider Monkey
electroCore, Inc. Q1 2026 Earnings Call Summary - Yahoo Finance
electroCore Q1 2026 Earnings Call Transcript - MarketBeat
electroCore reports Q1 EPS (59c) vs. (47c) last year - TipRanks
electroCore Q1 Earnings Call Highlights - Yahoo Finance
Earnings call transcript: Electrocore Q1 2026 revenue hits record high By Investing.com - Investing.com Canada
electroCore, Inc. (ECOR) Reports Q1 Loss, Beats Revenue Estimates - Yahoo Finance
Electrocore Inc Stock (ECOR) Financials Data
Revenue
Net Income
Cash Flow
EPS
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):